MIRA Pharmaceuticals (MIRA) announced that its stockholders have approved the acquisition of SKNY Pharmaceuticals at the Company’s 2025 Annual Meeting of Stockholders. All proposals at the meeting were approved by shareholders, including the SKNY acquisition. The Company expects the transaction to close shortly, subject to customary closing conditions. Under the terms of the definitive agreement, the acquisition will be structured as a share exchange, with SKNY shareholders receiving shares of MIRA common stock in exchange for their SKNY shares. At closing, SKNY shall contribute an amount of assets or cash totaling $5,000,000 to MIRA, reinforcing the Company’s financial position. Independent third-party valuation analyses conducted by Moore Financial Consulting assigned an enterprise value of approximately $30.5M to SKNY and $30M to MIRA, supporting a combined enterprise value of more than $60 million for the merged entity.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRA:
- MIRA Pharmaceuticals Approves 2022 Omnibus Incentive Plan
- Psychedelic: NRx Pharmaceuticals reports Q2 earnings
- Mira Pharmaceuticals completes Phase 1 SAD portion for oral Ketamir-2
- MIRA Pharmaceuticals Completes Phase 1 Trial for Ketamir-2
- Psychedelic: atai Life Sciences, Cybin report earnings results